STOCK TITAN
  1. Home
  2. News
  3. CMPS

COMPASS Pathways Plc American Depository Shares - $CMPS STOCK NEWS

Welcome to our dedicated page for COMPASS Pathways Plc American Depository Shares news (Ticker: $CMPS), a resource for investors and traders seeking the latest updates and insights on COMPASS Pathways Plc American Depository Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect COMPASS Pathways Plc American Depository Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of COMPASS Pathways Plc American Depository Shares's position in the market.

News
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
COMPASS Pathways reports financial results for Q3 2023, with a cash position of $248.0 million as of September 30, 2023. The COMP360 phase 3 program is ongoing, and top-line data for COMP005 is expected in summer 2024. The company also expects top-line data for its phase 2 study in PTSD by the end of this year. COMPASS secured up to $285 million in private placement financing. The CEO expressed confidence in the clinical programs and pre-commercial work for a potential new drug application filing with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
earnings
-
News
COMPASS Pathways announces CFO transition
Rhea-AI Summary
COMPASS Pathways announces CFO departure and appointment of interim CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
none
-
News
COMPASS Pathways appoints Daphne Karydas to its Board of Directors
Rhea-AI Summary
COMPASS Pathways appoints Daphne Karydas to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
management
News
COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
Rhea-AI Summary
COMPASS Pathways announces results of AI study on psilocybin treatment in depression
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
AI
-
News
COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
Rhea-AI Summary
COMPASS Pathways announces $125M private placement with healthcare specialist investors, with potential for additional $160M tied to exercise of warrants. Net proceeds expected to extend cash runway into late 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.46%
Tags
none
-
News
COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights  
Rhea-AI Summary
COMPASS Pathways reports Q2 2023 financial results and provides business update. Phase 3 trials for COMP360 ongoing and on track. CPT III code for psychedelic therapy support accepted by the American Medical Association. Cash position of $148.2 million as of June 30, 2023. Term loan facility secured up to $50 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
earnings
News
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
Rhea-AI Summary
CMPS: COMP360 Psilocybin Treatment Study Shows Potential in Anorexia Nervosa, Demonstrates Clinically Significant Reductions in Eating Disorder Psychopathology, Shape and Weight Concerns, and Positive Participant Experience
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
earnings clinical trial
-
News
COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
Rhea-AI Summary
COMPASS Pathways announces positive data from an open-label phase 2 clinical trial of COMP360 psilocybin in addition to SSRIs for treatment-resistant depression. Response and remission rates of 42% were observed at week three. COMP360 psilocybin treatment was generally well tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
clinical trial
-
News
Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
none
News
American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
none
Stock CMPS logo
COMPASS Pathways Plc American Depository Shares

Nasdaq:CMPS

CMPS Rankings

#2874 Ranked by Market Cap
#4661 Ranked by Stock Gains
N/A Ranked by Dividends

CMPS Stock Data

563.83M
36.86M
28.37%
39.91%
4.58%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CHESIRE

About CMPS

compass pathways is a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health. our first major initiative is developing psilocybin therapy through late-stage clinical trials in the eu and us for patients with treatment-resistant depression. we are developing psychoactive care pathways based on advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.